You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
SBIR Phase II: New Crystallization Modifiers for Low Calorie Fats in Food Products
SBC: TETRAMER TECHNOLOGIES LLC Topic: CTThe broader impact/commercial potential of this Small Business Innovation Research Phase II project is to facilitate the commercialization of low fat replacement EPG technology to help solve some of the largest obesity and related health issues facing the US while providing a patentable new additive platform for the $600 billion food industry. With high caloric density foods being the primary caus ...
SBIR Phase II 2016 National Science Foundation -
Structural Reactive Polymeric Materials
SBC: TETRAMER TECHNOLOGIES LLC Topic: MDA15004Missiles produced with reactive materials can add chemical energy to the kinetic energy generated on impact with a target. Thus, reactive materials have potential to serve as structural components resulting in possible increase lethality without a weight impact. In Phase I, Tetramer will demonstrate a new material system with significantly stronger mechanical properties and excellent reactive prop ...
SBIR Phase I 2016 Department of DefenseMissile Defense Agency -
SBIR Phase II: Reducing size and cost of optical devices with nanomanufacturing- a novel use of disk drive technology
SBC: MagAssemble, LLC Topic: MNThe broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is in advanced manufacturing. This project will develop a low cost, small-footprint high-resolution nanomanufacturing platform for building optical devices that are traditionally manufactured using cleanroom microlithography. Compared with modern cleanroom approaches that require significantl ...
SBIR Phase II 2016 National Science Foundation -
Novel Dental Adhesives to Prevent Recurrent Caries
SBC: CuRE Innovations, LLC Topic: NIDCRDESCRIPTION provided by applicant Bacterial related marginal decay is the top reason for failure and retreatment of resin based composite restorations RBCs Retreatment of these restorations costs both the patients and insurance companies billions of dollars per year The weak point of the system is the zone known as the hybrid layer where the adhesive bonds the RBC to the dentin There are ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel mechanism for the treatment of epilepsy: New Vitamin K analogs target energetics and have low toxicity due to excellent specificity and low dose requirements compared to current therapies
SBC: NEUROENE THERAPEUTICS INC Topic: 106DESCRIPTION provided by applicant Epilepsy is the th most common neurological disorder with in people developing epilepsy the occurrence of more than one unprovoked seizure at some point in their lifetime Unfortunately of all patients have intractable medication resistant epilepsy Thus new anti epileptic drugs AEDs that target alternative mechanisms of action are needed ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
An H/F/X/Y Fast-MAS NMR Probe Particularly for Alzheimer’s and Cancer Research
SBC: DOTY SCIENTIFIC, INC. Topic: 400DESCRIPTION provided by applicant More than of current drugs and a much greater fraction of those in development are fluorinated including such block busters as Prozac Lipitor and Ciprobay Steady progress over the past decade has shown magic angle spinning MAS solid state NMR ssNMR to be arguably the most powerful analytical tool for studying macro molecular structures and their ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Quad-Fast-MAS probe for Dramatically Improved Biomolecular Structure Determinations
SBC: DOTY SCIENTIFIC, INC. Topic: 400DESCRIPTION provided by applicant A Quad Fast MAS probe for Dramatically Improved Biomolecular Structure Determinations Abstract The last years have seen steady progress in applying magic angle spinning MAS NMR to an increasingly wide range of applications in structural biology However the methods are all far from routine and often require mg of a concentrated sample that is extrem ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Screening the Ribosome for New Target Sites
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple Myeloma MM is the second most common form of blood cancer and remains an incurable and deadly disease Proteasome inhibitor PI therapy is a cornerstone in the treatment of MM but resistance to this class of agent is an emerging challenge in the clinic New therapeutic approaches that specifically target resistance are needed to maximize responses and ultimate ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health